Metformin decreases the cardiovascular complications as well as all-cause mortality compare to other comparators. The overall risk of cancers is significantly greater in the diabetics compared to those without diabetes. Metformin has an anti-proliferative effect through activation of the adenosine monophosphate activated protein kinase. There is a lower risk of certain cancers in diabetics who were treated with metformin. Metformin in a small prospective study showed promising effect in decreasing thyroid nodule size in patients with insulin resistance and small thyroid nodule. Benefits of metformin extended to thyroid cancer patients, as it showed a smaller tumor size and increasing the likelihood for complete response compare to those weren’t treated with metformin. Diabetes and even hyperglycemia have been shown to increase risk of dementia. Diabetes also increases the risk of affective disorder, the combination of metformin and sulfonylurea minimizes this risk. Controversies do exist in some of the above evidence, but the potential benefits with the limited side effects are the reasons behind making metformin first line of treatment. The impact factor of journal provides quantitative assessment tool for grading, evaluating, sorting and comparing journals of similar kind. It reflects the average number of citations to recent articles published in science and social science journals in a particular year or period, and is frequently used as a proxy for the relative importance of a journal within its field. It is first devised by Eugene Garfield, the founder of the Institute for Scientific Information. The impact factor of a journal is evaluated by dividing the number of current year citations to the source items published in that journal during the previous two years.